Valuation: IMPACT Therapeutics, Inc

Market Cap 398.58Cr 461.47Cr 59Cr 51Cr 47Cr 44Cr 83Cr 5.66TCr 84Cr 566.83Cr 222.41Cr 2.77TCr 221.08Cr 216.23Cr 9.54TCr P/E 2026 *
-
P/E 2027 * -
Enterprise Value 315.35Cr 365.11Cr 47Cr 41Cr 38Cr 35Cr 65Cr 4.48TCr 67Cr 448.47Cr 175.96Cr 2.19TCr 174.91Cr 171.08Cr 7.55TCr EV / Sales 2026 *
11.4x
EV / Sales 2027 * 2.88x
Free-Float
-
Yield 2026 *
-
Yield 2027 * -
1 day-2.79%
1 week-14.57%
Current month-53.69%
1 month-54.69%
1 week 15.61
Extreme 15.61
19.96
1 month 15.61
Extreme 15.61
38
Current year 15.61
Extreme 15.61
47.98
1 year 15.61
Extreme 15.61
47.98
3 years 15.61
Extreme 15.61
47.98
5 years 15.61
Extreme 15.61
47.98
10 years 15.61
Extreme 15.61
47.98
Manager TitleAgeSince
Chief Executive Officer 69 01/06/2014
Director of Finance/CFO 51 01/05/2024
Chief Tech/Sci/R&D Officer 44 01/01/2025
Director TitleAgeSince
Director/Board Member 69 01/06/2014
Director/Board Member 69 01/06/2014
Director/Board Member 44 01/03/2025
Change 5-day change 1-year change 3-year change Capi.($)
-2.79%-14.57% - - 61Cr
-0.17%+1.47%+3.16%+6.80% 5.04TCr
-0.29%-2.81%+387.81%+591.82% 3.93TCr
-0.49%+1.48%+31.16%-6.46% 3.47TCr
+1.53%+3.11%+15.41%+58.54% 3.41TCr
+1.68%-0.62%+3.30%+27.34% 2.66TCr
+1.13%-3.11% - - 1.65TCr
-1.29%-0.52%+69.24%+117.60% 1.53TCr
+0.43%+3.34%+14.96%+17.46% 1.38TCr
+2.45%+3.99%+18.20%-30.12% 1.29TCr
Average +0.22%-0.63%+67.90%+97.87% 2.44TCr
Weighted average by Cap. +0.39%+0.75%+81.94%+122.30%

Financials

2026 *2027 *
Net sales 28Cr 32Cr 4.1Cr 3.58Cr 3.31Cr 3.04Cr 5.76Cr 394.43Cr 5.86Cr 39Cr 15Cr 192.79Cr 15Cr 15Cr 664.49Cr 94Cr 108.98Cr 14Cr 12Cr 11Cr 10Cr 20Cr 1.34TCr 20Cr 133.86Cr 53Cr 653.84Cr 52Cr 51Cr 2.25TCr
Net income - -
Net Debt -83Cr -96Cr -12Cr -11Cr -9.91Cr -9.11Cr -17Cr -1.18TCr -18Cr -118.37Cr -46Cr -578.16Cr -46Cr -45Cr -1.99TCr -127.74Cr -147.9Cr -19Cr -16Cr -15Cr -14Cr -27Cr -1.82TCr -27Cr -181.67Cr -71Cr -887.34Cr -71Cr -69Cr -3.06TCr
Logo IMPACT Therapeutics, Inc
IMPACT Therapeutics Inc is a China-based company mainly engaged in biotechnology research and commercialization. The Company is in the commercialization stage. The Company is committed to advancing synthetic lethality (SL)-based precision anti-cancer therapies globally. The Company's independently developed core product, senaparib, in China as a 1L maintenance therapy for ovarian cancer (OC). The Company is currently developing product pipeline packages such as PARP1/2, PARP1, ATR, WEE1, PKMYT1/WEE1, DHX9, ATM, USP1, and CHK1/2.
Employees
-
Date Price Change Volume
15/26/15 HK$16.71 -2.79% 6,04,700
14/26/14 HK$17.19 -4.82% 2,64,000
13/26/13 HK$18.06 -7.38% 2,79,400
10/26/10 HK$19.50 +1.14% 2,66,452
09/26/09 HK$19.28 -1.43% 2,94,400
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
1
Last Close Price
14.43CNY
Average target price
32.43CNY
Spread / Average Target
+124.70%

Net sales - Rate of surprise

  1. Stock Market
  2. Stocks
  3. 7630 Stock